Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
08 September 2020 - 10:30PM
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that the Company will be presenting at
upcoming investor and scientific conferences virtually:
- TIDES: Oligonucleotide and Peptide Therapeutics
scientific conference PresentationDate: Wednesday,
September 9, 2020Time: On-line
- Baird Global Healthcare
ConferencePresentationDate: Wednesday, September 9,
2020Time: 1:25 p.m. ET
- Citi 15th Annual BioPharma
ConferencePanelDate: Thursday, September 10, 2020Time:
1:30 p.m. ET
- UBS COVID-19 Vaccine Symposium Fireside
ChatDate: Friday, September 11, 2020Time: 3:50 p.m. ET
- H.C. Wainwright & Co. 22nd Annual Global Investment
ConferencePresentationDate: Monday, September 14,
2020Time: 11:00 a.m. ET
The events above may be accessed on the Arcturus
website in the Investors Relation section, under Events and
Presentations for approximately 30 days following the events.
About Arcturus
TherapeuticsFounded in 2013 and based in San Diego,
California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a
clinical-stage mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes self-replicating mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other
programs to potentially treat Ornithine Transcarbamylase (OTC)
Deficiency, Cystic Fibrosis, Cardiovascular Disease along with
partnered programs including Glycogen Storage Disease Type 3,
Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH).
Arcturus’ versatile RNA therapeutics platforms can be applied
toward multiple types of nucleic acid medicines including messenger
RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (192 patents and patent
applications, issued in the U.S., Europe, Japan, China and other
countries). Arcturus’ commitment to the development of novel RNA
therapeutics has led to collaborations with Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics
Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more
information visit www.ArcturusRx.com
IR and Media ContactsArcturus TherapeuticsNeda
Safarzadeh (858) 900-2682 IR@ArcturusRx.com
Kendall Investor RelationsCarlo Tanzi, Ph.D. (617)
914-0008 ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2023 to Apr 2024